Erik Ibarra's latest venture is to give agency to residents in the neighborhood he grew up in. Photo courtesy

Innovation isn't always tinkering with tech or programming software, although serial entrepreneur Erik Ibarra knows that world well. Sometimes it's about rethinking how a community improves and develops without doing the residents a disservice.

That's why Ibarra started Magnolia Fund, a mission-driven investment fund dedicated to enriching the East End community and preserving the neighborhood's culture and history. Ibarra, who has lived in the area the majority of his life, says on the Houston Innovators Podcast, that he's looking to turn residents into investors.

"Our investors from the neighborhood, today they walk around and look at their house and say, 'I own that,' and that's great," Ibarra says. "In the future, our investors should be able to say that, and then point to a building and say, 'I own a portion of that building too. And I helped that small business over there.'"

Ibarra explains that he's seen the East End area evolve a lot, and he wants to create a way to make sure residents are a part of that evolution and aren't being left behind in that process.

"Over the years, I've felt like there's so much development going on. But, the people from the neighborhood are very often just passive — they don't get a chance to benefit from or think about how they could participate in these new developments," Ibarra says. "The neighborhood is very close to my heart, and, about a year ago, I realized I wanted to do something about this."

The limited partners of the Magnolia Fund will contribute as investors, and then Ibarra and his team will identify a worthy development to take control of. As he explains, the vision for the property is "La Sala," a living room for the community, with an open area for communing, a kitchen incubator for food entrepreneurs, and an outdoor patio and stage for music and events.

While this is his first foray into the investor side of the equation, Ibarra has been an entrepreneur in Houston since the early 2000s. He's been an active mentor to startup founders, and has seen the ecosystem develop as he's started and grown his businesses.

He's currently the founder and CEO of ORDRS, a digital health platform for optimized lab testing founded in 2018. The company's B2B platform enables health care providers to better manage lab testing, and Ibarra says ORDRS saw a lot of growth during the pandemic. Something he's passionate about with this venture is the ability to provide better access and information about lab testing to patients.

"As a company we strive for transparency in health care," Ibarra says. "If we could provide instant access to a menu of tests for our customers, ... then hopefully our customers can pass those savings on to those customers. Access to testing is important. Access to the transparency in pricing is equally important."

Ibarra shares more about ORDRS, his role as a mentor, and his vision for the fund on the podcast. Listen to the interview below — or wherever you stream your podcasts — and subscribe for weekly episodes.


Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”

Chevron enters the lithium market with major Texas land acquisition

to market

Chevron U.S.A., a subsidiary of Houston-based energy company Chevron, has taken its first big step toward establishing a commercial-scale lithium business.

Chevron acquired leaseholds totaling about 125,000 acres in Northeast Texas and southwest Arkansas from TerraVolta Resources and East Texas Natural Resources. The acreage contains a high amount of lithium, which Chevron plans to extract from brines produced from the subsurface.

Lithium-ion batteries are used in an array of technologies, such as smartwatches, e-bikes, pacemakers, and batteries for electric vehicles, according to Chevron. The International Energy Agency estimates lithium demand could grow more than 400 percent by 2040.

“This acquisition represents a strategic investment to support energy manufacturing and expand U.S.-based critical mineral supplies,” Jeff Gustavson, president of Chevron New Energies, said in a news release. “Establishing domestic and resilient lithium supply chains is essential not only to maintaining U.S. energy leadership but also to meeting the growing demand from customers.”

Rania Yacoub, corporate business development manager at Chevron New Energies, said that amid heightening demand, lithium is “one of the world’s most sought-after natural resources.”

“Chevron is looking to help meet that demand and drive U.S. energy competitiveness by sourcing lithium domestically,” Yacoub said.

---

This article originally appeared on EnergyCapital.